Introduction {#s1}
============

Carcinogenesis is characterized by the alteration of the normal processes designated to maintain the genome stability. Apoptosis is the most prominent mechanism of the programmed cell-death, responsible for the safe removal of damaged cells before genome abnormalities can be replicated and further spread. Caspase enzymes are essential in the regulation and execution of most of the apoptotic cell-death pathways. In particular, caspase-8 (*CASP8*) is a crucial player in controlling the apoptosis of T lymphocytes through activation-induced cell-death [@pone.0085538-Krammer1] and, simultaneously, a physiological homeostasis of T lymphocytes is a fundamental aspect in the immune-surveillance of cancer cells.

A polymorphism consisting of the deletion of six nucleotides in the promoter region of *CASP8*, and referred as --652 6N del (rs3834129), has been described to be very common in several populations [@pone.0085538-Sun1]. This six-nucleotide deletion was shown to destroy a stimulatory protein 1 binding element in the promoter regulatory region that causes a decreased *CASP8* transcription and eventually a reduced apoptosis of antitumor T lymphocytes [@pone.0085538-Sun1]. Thus, rs3834129 was postulated to affect the antitumor immune response during cancer initiation or progression, and consequently considered as a genetic factor potentially associated with cancer risk. In this light, the polymorphism was tested in a case-control study and the del allele was shown to be associated with a protective effect in several types of cancer, including CRC, in the Chinese population [@pone.0085538-Sun1]. Two subsequent studies further investigated the effect of rs3834129 in CRC testing cases and controls of mixed and Caucasian ethnicity but failed to confirm the association [@pone.0085538-Haiman1], [@pone.0085538-Pittman1]. A meta-analysis of these three studies indicated that, under a dominant model, the del allele was associated with a significantly reduced risk for CRC with odds ratio (OR) = 0.89, 95% confidence interval (CI) = 0.83--0.96 [@pone.0085538-Yin1]. However, a later study not included in the above meta-analysis, again failed to reveal an association between rs3834129 and CRC risk in Chinese [@pone.0085538-Liu1].

Hence, in the present study we sought for more robust proof, whether rs3834129 may be a CRC risk factor in a case-control study, based on six cohorts recruited in centers located in Spain, Italy, USA, England, Czech Republic and the Netherlands and collaborating within the COGENT (COlorectal cancer GENeTics) consortium [@pone.0085538-Tomlinson1].

Materials and Methods {#s2}
=====================

Case-control cohorts {#s2a}
--------------------

The COGENT (COlorectal cancer GENeTics) consortium was established in 2007 with the main goal to study genetic susceptibility to CRC in a collaborative way. The consortium consisted in over 20 research groups in Europe, Australia, the Americas, China and Japan actively working on CRC genetics and with expertise encompassing genetic epidemiology, statistical genetics, gene mapping, biology, molecular genetics, pathology and diagnosis and the clinical management of CRC [@pone.0085538-Houlston1]. Maintaining its main objectives, the consortium has now evolved into a more structured initiative named "Cooperation Studies on Inherited Susceptibility to Colorectal Cancer" (EuCOLONGENE - <http://www.eucolongene.eu>). In the present study, rs3834129 was tested as genetic risk factor for CRC in six cohorts comprising 6,733 cases and 7,576 controls.

1\. Spanish cohort. Cases and controls were recruited through the EPICOLON Consortium that is based on a prospective, multicenter and population-based epidemiology survey of the incidence and features of CRC in the Spanish population [@pone.0085538-Abuli1]. Briefly, cases were selected as patients with *de novo* histologically confirmed diagnosis of colorectal adenocarcinoma. Exclusion criteria were hereditary CRC forms, such as hereditary non-polyposis colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP) and a personal history of inflammatory bowel disease. Controls were from the Spanish National DNA bank and were confirmed not to have cancer or history of neoplasm and no family history of CRC. All cases and controls were of Caucasian ethnicity. 2. Italian cohort. Cases and controls were recruited as described by [@pone.0085538-FernandezRozadilla1]. Briefly, the cases were consecutive individuals affected with CRC who underwent surgery at the Fondazione IRCCS Istituto Nazionale Tumori in Milan (INT). The controls were blood donors recruited through the Immunohematology and Transfusion Medicine Service of INT the Associazione Volontari Italiani Sangue Comunale in Milan. All cases and controls were of Caucasian ethnicity. 3. American cohort (Kentucky, USA). Cases and controls were recruited as recently described [@pone.0085538-Li1]. Briefly, incident colon cancer cases were identified through the Kentucky Cancer Registry. Population controls were recruited via random digit dialing according to the following criteria: being at least 30 years of age or older and free of personal history of cancer other than skin cancer. For both cases and controls, exclusion criteria were inflammatory bowel diseases, FAP and HNPCC. Majority of the participants were Caucasians (93.7%). 4. English cohort. Cases (CRC or significant adenomas) and controls were recruited through Colorectal Tumour Gene Identification (CoRGI) consortium as previously described [@pone.0085538-Tomlinson2]. Briefly, cases had at least one first-degree relative affected by CRC. The controls were spouses or partners unaffected by cancer and without a personal and family history of colorectal neoplasia. A single proband from each family was included in this study. Hereditary CRC forms such as, HNPCC/Lynch syndrome or bi-allelic MutYH mutation carriers were excluded. All cases and controls were of Caucasian ethnicity. 5. Czech Republic cohort. Cases and controls were recruited as previously described [@pone.0085538-Naccarati1]. Briefly, all cases had histologically confirmed CRC and were consecutively ascertained through oncological departments. Controls were either hospital-based volunteers with negative colonoscopy results or blood donors collected from a blood donor center in Prague. All cases and controls were of Caucasian ethnicity. 6. Dutch Cohort. Cases and controls were recruited as previously described [@pone.0085538-Middeldorp1]. Briefly, most of the cases were recruited through the clinical genetics department. All cases were diagnosed with CRC and had early onset and/or positive family history for CRC. Known dominant polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic MutYH mutation carriers were excluded. A single proband from each family was included in this study. Controls were healthy blood donors from the southwest region of the Netherlands. All cases and controls were of Caucasian ethnicity.

For each cohort, number of cases and controls included in the study and their sex and age data are shown in [Table 1](#pone-0085538-t001){ref-type="table"}. All individuals participating in this study signed an informed consent to the use of their biological samples for research purposes. This study was approved by the following Institutions: Clinical Research Ethics and Research Committees of the Hospital Clínic in Barcelon (Spanish cohort); Ethics Committee of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (Italian cohort); Institutional Review Boards of the University of Kentucky, Lexington, Case Western Reserve University/University Hospitals of Cleveland and University of Southern California, USA (American cohort); Southampton and South-West Hampshire Research Ethics Committee (English cohort); Ethics Committee of the Institute of Experimental Medicine, and Ethics Committee of the Institute for Clinical and Experimental Medicine and Thomayer Hospital, Prague, Czech Republic (Czech Republic cohort); the Medical Ethical Committee of the Leiden University Medical Center, The Netherlands (protocol P01.019) (Dutch cohort).

10.1371/journal.pone.0085538.t001

###### Characteristics of the cohorts included in the study.

![](pone.0085538.t001){#pone-0085538-t001-1}

  Cohort         Group                     N                          Age         Female (%)     Male (%)
  ------------ --------- -------------------------------------- ---- ----- ----- ------------- -------------
  Spanish        Case                     1978                   26   72    101   778 (39.3)    1200 (60.7)
                Control                   1647                   19   66    95    748 (45.4)    899 (54.6)
  Italian        Case                     617                    24   64    91    243 (39.4)    374 (60.6)
                Control                   2551                   18   44    71    1619 (63.5)   932 (36.5)
  USA            Case                     1010                   23   65    90    501 (49.6)    509 (50.4)
                Control                   1580                   31   61    91    1017 (64.4)   563 (35.6)
  English        Case                     1576                   18   65    89    712 (45.2)    864 (54.8)
                Control                   767                    18   56    86    462 (60.2)    305 (39.8)
  Czech Rep.     Case                     967                    26   62    89    393 (40.6)    574 (59.4)
                Control                   672                    24   57    91    314 (46.7)    358 (53.3)
  Dutch          Case     585[\*](#nt101){ref-type="table-fn"}   19   52    90    293 (50.1)    261 (44.6)
                Control                   359                         NA              NA            NA

Data on sex were missing for 31 cases.

Genotyping {#s2b}
----------

The genomic DNA was isolated from peripheral blood lymphocytes using standard procedures. The DNA samples from cases and controls were randomly aliquot in 96-well plates. Genotyping of the rs3834129 was carried out by using the Taqman assay (Life Technologies/Applied Biosystems, US) in the Spanish, Italian, USA and Dutch cohorts and using the KASPar assay (K-bioscience, UK) in the English and Czech Republic cohorts. Duplicate samples (5%), no template controls in each plate, and Hardy--Weinberg equilibrium test were used as quality control tests.

Statistical analysis {#s2c}
--------------------

Within each cohort, a logistics regression analysis [@pone.0085538-Hosmer1] was carried out in order to compare the genotypes frequency of *CASP8* rs3834129 in cases and controls. We estimated the odds ratio (OR) and their relative 95% confidence interval (CI) by considering in each logistic model age and sex as adjustment covariates. Four different models ("three genotypes", dominant, recessive and per allele) were performed for each cohort separated and considering all the individuals together. In this case, the variable with the indication of the cohort and the interaction term between this variable and the genotype were included in the logistic model in addition to the variables genotype, age and sex. The deviations of the genotype frequencies in the controls from those expected under Hardy-Weinberg equilibrium (HWE) were assessed within each cohort as well as by considering all individuals using Pearson\'s chi-squared test. All statistical analyses were performed with the SAS software (Version 9.2; SAS Institute Inc. Cary, NC).

Results and Discussion {#s3}
======================

In this study, we analyzed the rs3834129 genotype distribution in a total of 6,733 cases and 7,576 controls from six cohorts, all of Caucasian ethnicity. The genotype distributions in controls were consistent with HWE in all the cohorts and across them the frequencies of the del allele were similar in controls (range: 0.45--0.52). We performed an overall analysis to compare the genotypes frequency of *CASP8* rs3834129 in cases with CRC and in healthy controls. As in the Dutch controls data on sex and/or age were missing ([Table 1](#pone-0085538-t001){ref-type="table"}), this cohort was excluded from the overall analysis and a total of 6,148 cases and 7,217 controls were considered. All cohorts were based on incident/consecutive cases except for the English cohort which was based on familial cases. Therefore, we also performed an additional overall analysis excluding the English cohort and testing a total of 4,572 cases and 6,450 controls. In both these analyses the interaction term between cohort and genotype was not statistically significant and also the ORs derived from the different implemented genetic models were not statistically significant (data not shown).

Furthermore, we assessed the effect of rs3834129 on CRC risk within each cohort. The OR estimates were adjusted for sex and age with the only exception of Dutch cohort, results are reported in [Table 2](#pone-0085538-t002){ref-type="table"}. The ORs of the different implemented models (three genotypes, dominant, recessive and per-allele model) largely confirmed the results of the overall analysis being non statistically significant in each cohort with the only exception of the English one. The ORs in familial case-control samples from England were statistically significant (per allele model OR = 0.79, 95% CI = 0.69--0.90) indicating the del allele might be a protective factor versus familial cancer. This result may be explained considering that the familial cases, with respect to incident/consecutive cases, can be a better resource for association testing since they are expected to be enriched by genetic risk factors, or conversely, deprived by factors with a protective effect.

10.1371/journal.pone.0085538.t002

###### Genotype/allele frequencies of rs3834129 SNP in COGENT consortium cohorts and risk of CRC (logistic regression analysis).

![](pone.0085538.t002){#pone-0085538-t002-2}

  Cohort        Genetic model    Case (%)    Control (%)    OR      95% CI     p-value
  ------------ --------------- ------------ ------------- ------ ------------ ---------
  Spanish          nor/nor      500 (25.3)   425 (25.8)    1,00               
                   nor/del      996 (50.3)   802 (48.7)    1,06   0.90--1.26    0,452
                   del/del      482 (24.4)   420 (25.5)    0,96   0.79--1.16    0,651
                  Dominant                                 1,03   0.88--1.20    0,730
                  Recessive                                0,92   0.78--1.07    0,283
                   Allelic                                 0,98   0.89--1.08    0,658
  Italian          nor/nor      195 (31.6)   783 (30.7)    1,00               
                   nor/del      285 (46.2)   1230 (48.2)   0,93   0.72--1.21    0,609
                   del/del      137 (22.2)   538 (21.1)    0,85   0.62--1.16    0,313
                  Dominant                                 0,91   0.71--1.15    0,432
                  Recessive                                0,89   0.68--1.16    0,385
                   Allelic                                 0,92   0.79--1.08    0,306
  USA              nor/nor      237 (23.5)   383 (24.2)    1,00               
                   nor/del      514 (50.9)   794 (50.2)    1,07   0.88--1.31    0,501
                   del/del      259 (25.6)   403 (25.5)    1,04   0.83--1.32    0,678
                  Dominant                                 1,06   0.88--1.28    0,521
                  Recessive                                1,00   0.83--1.20    0,984
                   Allelic                                 1,02   0.91--1.15    0,689
  English          nor/nor      410 (26.0)   165 (21.5)    1,00               
                   nor/del      825 (52.4)   393 (51.2)    0,79   0.62--1.00    0,051
                   del/del      341 (21.6)   209 (27.3)    0,61   0.47--0.81    0,001
                  Dominant                                 0,73   0.58--0.91    0,006
                  Recessive                                0,72   0.58--0.90    0,003
                   Allelic                                 0,79   0.69--0.90   0,0006
  Czech Rep.       nor/nor      239 (24.7)   169 (25.1)    1,00               
                   nor/del      479 (49.5)   326 (48.5)    1,04   0.82--1.34    0,724
                   del/del      249 (25.7)   177 (26.3)    0,98   0.74--1.31    0,922
                  Dominant                                 1,02   0.81--1.29    0,838
                  Recessive                                0,96   0.76--1.20    0,708
                   Allelic                                 0,99   0.86--1.14    0,915
  Dutch            nor/nor      169 (28.9)   106 (29.5)    1,00               
                   nor/del      282 (48.2)   177 (49.3)    1,00   0.74--1.36    0,996
                   del/del      134 (22.9)    76 (21.2)    1,11   0.76--1.60    0,596
                  Dominant                                 1,03   0.77--1.38    0,834
                  Recessive                                1,11   0.80--1.52    0,534
                   Allelic                                 1,05   0.87--1.26    0,616

To our knowledge, this is the largest analysis testing the association between rs3834129 and CRC risk in Caucasians and our data provide the stronger and unambiguous evidence so far that the rs3834129 is not a CRC risk factor in this ethnic group. While our analysis was ongoing, other studies appeared, showing inconsistent results. On one side, lack of association was found in case-control analyses based on Greek and Chinese populations [@pone.0085538-Xiao1], [@pone.0085538-Theodoropoulos1]; on the other side, a meta-analysis, based on three studies of mix ethnicity, and a separate additional study on Chinese showed a moderately protective effect of the del allele [@pone.0085538-Wu1], [@pone.0085538-Zhang1]. Our findings in Caucasians, with respect to the putative protective effect detected in Chinese---that has to be confirmed by further larger studies---might be explained by additional risk-associated variants in linkage with rs3834129 and with different frequency in different ethnic genetic backgrounds. Specifically, the del allele of rs3834129 has a 0.48 control frequency in our study while we derived a frequency of 0.20--0.25 in Chinese controls [@pone.0085538-Sun1], [@pone.0085538-Liu1], [@pone.0085538-Xiao1], [@pone.0085538-Wu1].

In conclusion, while further studies are needed to confirm the protective effect of the del allele we observed in familial CRC cases with family history, our study provides robust evidence indicating the rs3834129 is not a risk factor for CRC in Caucasians.
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